Last Thursday, May 17, 2018, the FDA approved the novel new migraine medication, Aimovig. It’s in a new class of drugs that works by blocking the activity of a gene involved in migraines. The drug does not prevent all attacks but can lessen the severity and frequency by at least 50%. In clinical trials, side-effects reported were minimal. It’s administered once per month by injection and costs about $500+ per month or up to $7,000 per year.

As promising as this new class of drugs is, the long-term side-effects are undetermined, which takes us to another safety subject, a May 2017 study finds nearly one-third of FDA-approved medications between 2001 and 2010 had problems.

During that period, out of the 222 newly approved therapeutics, 123 safety events were reported in 71 products requiring the FDA to act. There were 61 warnings required to be added to the product boxes, indicating serious or life-threatening risks by the manufacturers. The study found that products that went through an accelerated approval process had a higher number of events.

In being your own health advocate, you need to wonder how safe drugs really are, which have been approved by the FDA. For example, you may recall back in 2005, the popular arthritis drug Bextra was pulled by the FDA after it had been approved because of its risks of heart, stomach, and skin problems.

Chiropractic Care – A Safe Alternative

In a June 2011 study appearing in JMPT concluded “evidence suggests that chiropractic care, including spinal manipulation, improves migraine and cervicogenic headaches. The type, frequency, dosage, and duration of treatment(s) should be based on guideline recommendations, clinical experience, and findings”.

Why not take a safe, drug-free route first with chiropractic care? Give us a call today!


Bryans R1, Descarreaux M, Duranleau M, Marcoux H, Potter B, Ruegg R, Shaw L, Watkin R, White E, Journal of Manipulative and Physiologic Therapeutics (JMPT), Evidence-based guidelines for the chiropractic treatment of adults with headache, June 2011